4. Issues of Ethnopharmacology in HIV Management
Future Role of Pharmacogenomics
Although the considerable variability among individuals in antiretroviral treatment outcomes in terms of efficacy and adverse events is due to multiple factors (including age, gender, ethnicity, body mass index, and coadministered drugs), there is wide agreement that host genetics play a significant role. As many as 50% of patients discontinue HAART due to adverse drug reactions or virologic failure. [Calmy 2007, Deeks 2000] With the great racial and ethnic diversity of the HIV-positive population and the potential association of HAART failure with racially associated genetic factors, the benefits of minimizing drug toxicities and enhancing patient and community virologic outcomes through the use of predictive tests are clear. Pharmacogenomics offers the potential to make such benefits a reality.
Traditionally, pharmacogenomics primarily examined patients’ nuclear genetic polymorphisms as a way to predict treatment-related adverse events. However, in an effort to address antiretroviral-associated adverse events as comprehensively as possible, pharmacogenomic testing has grown to include molecular assays that characterize extranuclear genetic material (such as HIV and mitochondrial genomes), in addition to patients’ nuclear genetic material. In the future, HIV-related applications of pharmacogenomic testing may also address, for instance, detection of mitochondrial depletion as an early surrogate marker for potential drug toxicity, qualitative analysis of host immune haplotypes, and metabolic/transporter genetic polymorphisms for predicting disease progression. Pharmacogenomic applications already in use in regard to prescribing abacavir and efavirenz offer proof of the clinical utility of pharmacogenomic testing to improve outcomes for patients who need to receive complex, probably life-long drug regimens. [Payne 2004] The stage is being set for an era of more personalized antiretroviral treatment.